startup.bid
ZH
EnglishEspañolPortuguêsFrançaisDeutschItalianoNederlandsSvenskaDanskNorskPolskiSlovenščinaTürkçeРусскийBahasa IndonesiaBahasa MelayuFilipinoTiếng ViệtKiswahiliहिन्दीاردوالعربيةעברית日本語한국어中文繁體中文

zPREDICTA

Patient-derived 3D tissue reconstruction models for preclinical…

已被收购

公司介绍

公司介绍(英文)

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic.

Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.

主题

所在地
旧金山, CA, 美国
团队规模
2 名员工
YC 批次
Summer 2015
状态
已被收购
阶段
早期阶段

同类创业公司与竞争对手

问答

zPREDICTA 的总部在哪里?

旧金山, CA, 美国

zPREDICTA 有多少名员工?

根据公司资料,共有 2 名员工。

zPREDICTA 获得过融资吗?

我们的数据中没有 zPREDICTA 的融资记录。

zPREDICTA 有哪些同类公司和竞争对手?

同类创业公司:Numerion Labs、Verge Genomics和PostEra。